Comparative Pharmacology
Head-to-head clinical analysis: ACYCLOVIR SODIUM versus FUZEON.
Peer-Reviewed Evidence
Head-to-head clinical analysis: ACYCLOVIR SODIUM versus FUZEON.
ACYCLOVIR SODIUM vs FUZEON
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Acyclovir is a synthetic nucleoside analogue with activity against herpes simplex virus (HSV) types 1 and 2, and varicella-zoster virus (VZV). It is converted to acyclovir monophosphate by viral thymidine kinase, then further phosphorylated to acyclovir triphosphate, which competitively inhibits viral DNA polymerase and incorporates into viral DNA, causing chain termination.
Fusion inhibitor; binds to gp41 of HIV-1, preventing conformational changes required for fusion with host CD4+ T-cell membrane.
Dosing is indication-specific. For herpes simplex encephalitis: 10 mg/kg IV every 8 hours for 10–14 days (adults and children ≥12 years) or 20 mg/kg IV every 8 hours (3 months–12 years). For severe genital herpes: 5 mg/kg IV every 8 hours for 5 days. For mucocutaneous HSV in immunocompromised: 5 mg/kg IV every 8 hours for 7–14 days. For varicella zoster in immunocompromised: 10 mg/kg IV every 8 hours for 7 days. For neonatal HSV: 20 mg/kg IV every 8 hours for 14–21 days (disseminated/CNS) or 14 days (skin/eyes/mouth).
90 mg subcutaneously twice daily
None Documented
None Documented
Terminal elimination half-life: 2.5-3.3 hours in adults with normal renal function; up to 20 hours in anuria/end-stage renal disease.
Terminal elimination half-life: 3.8 hours; clinically, steady-state plasma concentrations are achieved within 2-3 days with subcutaneous administration
Primarily renal excretion via glomerular filtration and tubular secretion: 62-91% of dose excreted unchanged in urine within 24 hours; minor biliary/fecal elimination (<2%).
Renal: approximately 70% as unchanged drug via glomerular filtration; fecal: <5% as metabolites
Category A/B
Category C
Antiviral
Antiviral